Hanmi Pharmaceutical began prescription availability for Efpe, South Korea's first domestic GLP-1 obesity drug, at select medical facilities on 29 October 2026.^[1] In June 2024, South Korea's Ministry of Food and Drug Safety proposed classifying GLP-1 class obesity drugs as medicines at risk of misuse.^[2] No national regulatory authority outside South Korea has classified GLP-1 obesity medications as misuse risk drugs.^[3] Reed Jobs has stated GLP-1 drugs may reduce cancer risk by addressing obesity. The CDC links obesity to 13 types of cancer, and estimates obesity-associated cancers account for 40% of all cancer diagnoses in the United States each year.^[4][5]